SG11201608194VA - Modified j-chain - Google Patents

Modified j-chain

Info

Publication number
SG11201608194VA
SG11201608194VA SG11201608194VA SG11201608194VA SG11201608194VA SG 11201608194V A SG11201608194V A SG 11201608194VA SG 11201608194V A SG11201608194V A SG 11201608194VA SG 11201608194V A SG11201608194V A SG 11201608194VA SG 11201608194V A SG11201608194V A SG 11201608194VA
Authority
SG
Singapore
Prior art keywords
chain
modified
Prior art date
Application number
SG11201608194VA
Inventor
Bruce Keyt
Leonard George Presta
Fen Zhang
Ramesh Baliga
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of SG11201608194VA publication Critical patent/SG11201608194VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
SG11201608194VA 2014-04-03 2015-04-02 Modified j-chain SG11201608194VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974738P 2014-04-03 2014-04-03
PCT/US2015/024149 WO2015153912A1 (en) 2014-04-03 2015-04-02 Modified j-chain

Publications (1)

Publication Number Publication Date
SG11201608194VA true SG11201608194VA (en) 2016-10-28

Family

ID=52998235

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608194VA SG11201608194VA (en) 2014-04-03 2015-04-02 Modified j-chain
SG10201909716R SG10201909716RA (en) 2014-04-03 2015-04-02 Modified j-chain

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201909716R SG10201909716RA (en) 2014-04-03 2015-04-02 Modified j-chain

Country Status (21)

Country Link
US (5) US10400038B2 (en)
EP (3) EP4011910A1 (en)
JP (2) JP6744822B2 (en)
KR (3) KR20230155600A (en)
CN (2) CN106459213B (en)
AU (3) AU2015240595B2 (en)
BR (1) BR112016022841B1 (en)
CA (1) CA2944647A1 (en)
DK (2) DK3560954T3 (en)
ES (2) ES2717704T3 (en)
HU (2) HUE042829T2 (en)
IL (3) IL292311A (en)
MX (2) MX2019008359A (en)
NZ (1) NZ725568A (en)
PL (2) PL3560954T3 (en)
PT (2) PT3560954T (en)
RU (2) RU2021134101A (en)
SG (2) SG11201608194VA (en)
SI (2) SI3560954T1 (en)
WO (1) WO2015153912A1 (en)
ZA (1) ZA201606906B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015053887A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
MX2016005170A (en) 2013-10-25 2017-02-02 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes.
BR112016018313A8 (en) 2014-02-10 2018-06-12 Igm Biosciences Inc IGA MULTI-SPECIFIC BINDING MOLECULES
PL3560954T3 (en) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Modified j-chain
SG11201705116SA (en) 2015-01-20 2017-08-30 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
ES2874558T3 (en) * 2015-03-04 2021-11-05 Igm Biosciences Inc CD20-binding molecules and their uses
JP6882184B2 (en) * 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド Multivalent hepatitis B virus antigen-binding molecule and its use
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
DK3356401T3 (en) * 2015-09-30 2020-09-07 Igm Biosciences Inc BINDING MOLECULES WITH MODIFIED J-CHAIN
CA2999284C (en) * 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
EA201891022A1 (en) * 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед VIRUS CODING ANTIBODY TO THE TCR COMPLEX OR THE FRAMED ANTIBODY
IL262295B2 (en) 2016-05-09 2023-09-01 Igm Biosciences Inc Anti-pd-l1 antibodies
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
ES2955074T3 (en) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteins that bind to HER2, NKG2D and CD16
JP2020512820A (en) 2017-04-07 2020-04-30 アイジーエム バイオサイエンシズ インコーポレイテッド Modified human IgM constant region for regulation of effector function of complement dependent cytolysis
BR112020016190A2 (en) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. ANTIBODY VARIABLE DOMAINS DIRECTING THE NKG2D RECEIVER
CA3091144A1 (en) * 2018-03-01 2019-09-06 Igm Biosciences, Inc. Igm fc and j-chain mutations that affect igm serum half-life
KR20220045019A (en) * 2019-08-15 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 Immunostimulatory multimeric binding molecule
WO2021055765A2 (en) * 2019-09-19 2021-03-25 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
CN115052884A (en) * 2019-09-27 2022-09-13 北京烁星生物医药科技有限公司 Monospecific and multispecific antibodies
JP2023522962A (en) 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド PD-1 agonist multimer binding molecules
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
WO2023196995A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
EP0642585B1 (en) 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (en) 1993-08-02 2001-08-15 Мерк Патент Гмбх Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0822941B1 (en) 1995-04-19 2002-06-12 Polymun Scientific Immunbiologische Forschung GmbH Monoclonal antibodies against hiv-1 and vaccines made thereof
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6045774A (en) * 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
US7311912B1 (en) 1997-01-10 2007-12-25 Plantbodies Corporation Epithelial tissue targeting agent
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
AU3655899A (en) 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
CN101518648A (en) 1999-01-07 2009-09-02 津莫吉尼蒂克斯公司 Soluble receptor BR43x2 and methods of using
EP1169352A4 (en) 1999-04-14 2005-05-04 Smithkline Beecham Corp Erythropoietin receptor antibodies
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7074403B1 (en) 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
AU6781700A (en) 1999-08-17 2001-03-13 Health Research Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
SI2857516T1 (en) 2000-04-11 2017-09-29 Genentech, Inc. Multivalent antibodies and uses therefor
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
AU5744501A (en) * 2000-04-28 2001-11-12 Planet Biotechnology Inc Novel immunoadhesin for the prevention of rhinovirus infection
EP1328293B1 (en) 2000-05-10 2012-02-15 Signe BioPharma Inc. Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
IL153853A0 (en) 2000-07-10 2003-07-31 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
EP1319025A2 (en) 2000-09-07 2003-06-18 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
AU2004297218B2 (en) 2000-09-07 2012-03-01 Amgen, Inc. Human anti-Pseudomonas-aeruginosa antibodies derived from transgenic Xenomouse
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR100900176B1 (en) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 Expression technology for proteins containing a hybrid isotype antibody moiety
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
NZ513418A (en) 2001-08-07 2004-04-30 Univ Massey Vaccine comprising proteins from mycobacterium paratuberculosis
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
JP4498746B2 (en) 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド Anti-CD20 antibody and fusion protein thereof and method of use
EP1483295B1 (en) 2002-03-01 2008-12-10 Immunomedics, Inc. Rs7 antibodies
EP1503794B9 (en) 2002-04-12 2012-09-19 Medarex, Inc. Methods of treatement using ctla-4 antibodies
EP1519958B1 (en) 2002-06-14 2014-10-15 Immunomedics, Inc. Humanized monoclonal antibody hpam4
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN101537180B (en) 2002-07-18 2016-02-10 莫鲁斯有限公司 The recombinant production of mixtures of antibodies
KR101115797B1 (en) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
ATE469920T1 (en) 2003-05-23 2010-06-15 Crucell Holland Bv PRODUCTION OF RECOMBINANT IGM IN THE PER.C6 CELLS
AU2004256354B2 (en) 2003-07-15 2011-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
DK1673398T3 (en) 2003-10-16 2011-04-18 Micromet Ag Multispecific, deimmunized CD3 binders
FR2861255B1 (en) 2003-10-24 2006-02-17 Centre Nat Rech Scient NON-HUMAN TRANSGENIC MAMMAL FOR THE CONSTANT REGION OF THE HEAVY CHAIN OF HUMAN CLASS A IMMUNOGLOBULINS AND ITS APPLICATIONS
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CN101098889A (en) 2004-11-05 2008-01-02 盘林京有限公司 Antibody induced cell membrane wounding
US7251164B2 (en) 2004-11-10 2007-07-31 Innovative Silicon S.A. Circuitry for and method of improving statistical distribution of integrated circuits
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
AU2006218454B2 (en) 2005-03-03 2011-11-17 Immunomedics, Inc. Humanized L243 antibodies
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US20110129412A1 (en) 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056142A1 (en) 2005-10-21 2007-09-19 Amgen Inc METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY
WO2007073499A2 (en) 2005-12-21 2007-06-28 Medimmune, Inc. Epha2 bite molecules and uses thereof
CN101506358B (en) 2006-05-15 2013-07-17 免疫医学股份有限公司 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2007134384A2 (en) 2006-05-19 2007-11-29 Children Youth And Women's Health Service Selective modulation of receptor signalling
MX2008015524A (en) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function.
EP3339445B1 (en) 2006-09-08 2020-07-15 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
SG176476A1 (en) 2006-11-02 2011-12-29 Daniel J Capon Hybrid immunoglobulins with moving parts
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US20100184959A1 (en) 2007-03-19 2010-07-22 Medimmune Limited Polypeptide Variants
WO2008135963A2 (en) 2007-05-02 2008-11-13 Hemogem Inc. Fibrinogen for treatment of bleeding in trauma and platelet disorders
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
WO2009030285A1 (en) 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2219458B1 (en) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
ITTO20080313A1 (en) 2008-04-22 2009-10-23 Marco Colombatti ISOLATED MONOCLONAL ANTIBODY OR ITS FRAGMENT BINDING THE PROSTATE'S SPECIFIC MEMBRANE ANTIGEN, ITS CONJUGATES AND ITS USES
EP2300498A2 (en) 2008-07-11 2011-03-30 Sea Lane Biotechnologies,llc. Constructs and libraries comprising antibody surrogate kappa light chain sequences
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 CD20 antibody and uses thereof
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
NZ609607A (en) 2010-10-19 2014-12-24 Mayo Foundation Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
AU2012328917B2 (en) 2011-10-24 2017-05-25 Abbvie Inc. Bispecific immunobinders directed against TNF and IL-17
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
MX363819B (en) 2012-02-08 2019-04-03 Igm Biosciences Inc Cdim binding proteins and uses thereof.
JP6238958B2 (en) 2012-04-05 2017-11-29 ゴットフリート・ヒムラー Secretory immunoglobulin complex
JP6162219B2 (en) * 2012-04-17 2017-07-12 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Human antibodies and their specific binding sequences for use in stroke and ischemia or ischemic conditions
WO2013188870A2 (en) 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
CN103570821A (en) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 Mucin-1 antigenic polypeptide and application thereof as tumor vaccine
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
US10066238B2 (en) 2013-02-11 2018-09-04 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
WO2015053887A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
KR102056963B1 (en) 2013-12-30 2019-12-17 에피맙 바이오테라퓨틱스 인코포레이티드 Fabs-in-tandem immunoglobulin and uses thereof
CA2936877C (en) 2014-01-16 2023-03-28 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
BR112016018313A8 (en) 2014-02-10 2018-06-12 Igm Biosciences Inc IGA MULTI-SPECIFIC BINDING MOLECULES
CU24481B1 (en) 2014-03-14 2020-03-04 Immutep Sas ANTIBODY MOLECULES THAT JOIN LAG-3
PL3560954T3 (en) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Modified j-chain
SG11201705116SA (en) 2015-01-20 2017-08-30 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
ES2874558T3 (en) 2015-03-04 2021-11-05 Igm Biosciences Inc CD20-binding molecules and their uses
JP6882184B2 (en) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド Multivalent hepatitis B virus antigen-binding molecule and its use
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
DK3356401T3 (en) 2015-09-30 2020-09-07 Igm Biosciences Inc BINDING MOLECULES WITH MODIFIED J-CHAIN
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
IL262295B2 (en) 2016-05-09 2023-09-01 Igm Biosciences Inc Anti-pd-l1 antibodies
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
JP2019528683A (en) 2016-07-20 2019-10-17 アイジーエム バイオサイエンシズ インコーポレイテッド Multimeric GITR binding molecules and uses thereof
AU2017298483A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric OX40 binding molecules and uses thereof
JP2020512820A (en) 2017-04-07 2020-04-30 アイジーエム バイオサイエンシズ インコーポレイテッド Modified human IgM constant region for regulation of effector function of complement dependent cytolysis
US20200392239A1 (en) 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CA3091144A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. Igm fc and j-chain mutations that affect igm serum half-life
CA3113268A1 (en) 2018-10-23 2020-04-30 Igm Biosciences, Inc. Multivalent igm- and iga-fc-based binding molecules
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
KR20220045019A (en) 2019-08-15 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 Immunostimulatory multimeric binding molecule
CA3147767A1 (en) 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
KR20220050166A (en) 2019-08-23 2022-04-22 아이쥐엠 바이오사이언스 인코포레이티드 IGM Glycovariant
WO2021055765A2 (en) 2019-09-19 2021-03-25 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
IL293739A (en) 2020-01-06 2022-08-01 Igm Biosciences Inc Highly sialylated multimeric binding molecules
JP2023522962A (en) 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド PD-1 agonist multimer binding molecules
JP2023526224A (en) 2020-05-12 2023-06-21 アイジーエム バイオサイエンシズ インコーポレイテッド Use of multimeric anti-DR5 binding molecules in combination with cancer therapeutics to treat cancer
CA3187008A1 (en) 2020-07-27 2022-02-03 Paul R. Hinton Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
WO2022177870A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
JP2024508709A (en) 2021-02-17 2024-02-28 アイジーエム バイオサイエンシズ インコーポレイテッド Anti-CD123 binding molecules and methods of use thereof

Also Published As

Publication number Publication date
IL292311A (en) 2022-06-01
SG10201909716RA (en) 2019-11-28
EP3126383B1 (en) 2018-12-19
ZA201606906B (en) 2021-07-28
CN106459213A (en) 2017-02-22
PL3560954T3 (en) 2021-12-13
BR112016022841A2 (en) 2017-10-17
MX2019008359A (en) 2019-09-16
ES2887299T3 (en) 2021-12-22
AU2015240595B2 (en) 2020-02-27
EP3126383A1 (en) 2017-02-08
JP2017512815A (en) 2017-05-25
EP3560954B1 (en) 2021-08-04
US20200190190A1 (en) 2020-06-18
US20190002566A1 (en) 2019-01-03
CN112759650A (en) 2021-05-07
KR20160142345A (en) 2016-12-12
JP7062025B2 (en) 2022-05-02
PL3126383T3 (en) 2019-08-30
WO2015153912A1 (en) 2015-10-08
MX366588B (en) 2019-07-15
AU2022201585A1 (en) 2022-03-31
EP3126383B8 (en) 2019-02-27
NZ725568A (en) 2022-10-28
EP3560954A1 (en) 2019-10-30
BR112016022841B1 (en) 2023-09-26
MX2016012880A (en) 2017-05-12
HUE055693T2 (en) 2021-12-28
DK3126383T3 (en) 2019-04-01
JP6744822B2 (en) 2020-08-19
US11555075B2 (en) 2023-01-17
KR20230155600A (en) 2023-11-10
AU2015240595A1 (en) 2016-11-03
US20170183409A1 (en) 2017-06-29
AU2020201347A1 (en) 2020-03-12
DK3560954T3 (en) 2021-09-06
US10975147B2 (en) 2021-04-13
IL248151A0 (en) 2016-11-30
US10400038B2 (en) 2019-09-03
RU2016141579A3 (en) 2018-12-26
EP4011910A1 (en) 2022-06-15
RU2016141579A (en) 2018-05-10
RU2021134101A (en) 2022-03-22
PT3560954T (en) 2021-09-07
JP2020114828A (en) 2020-07-30
ES2717704T3 (en) 2019-06-24
KR102380402B1 (en) 2022-03-31
CA2944647A1 (en) 2015-10-08
CN106459213B (en) 2020-12-01
BR112016022841A8 (en) 2018-06-12
RU2761118C2 (en) 2021-12-06
US20170283510A1 (en) 2017-10-05
US20230279111A1 (en) 2023-09-07
SI3126383T1 (en) 2019-05-31
AU2020201347B2 (en) 2022-03-10
IL278350B (en) 2022-06-01
PT3126383T (en) 2019-03-22
SI3560954T1 (en) 2021-11-30
HUE042829T2 (en) 2019-07-29
US9951134B2 (en) 2018-04-24
KR20220044377A (en) 2022-04-07

Similar Documents

Publication Publication Date Title
ZA201606906B (en) Modified j-chain
DK3373003T3 (en) Urinteststrimmel
AU361515S (en) Dishrack
PL3097397T3 (en) Schienenmesssystem
AU362944S (en) Lapboard
DK3191586T3 (en) Cellobiosephosphorylase
DK3002465T3 (en) Hydrauliksystem
GB2536404B (en) Dehumidifer
GB201419650D0 (en) Modified heterocyclase
GB201406378D0 (en) Turretflow
DK3145380T3 (en) Toiletventilationssystem
GB2529833B (en) Bazometer
AU5593P (en) Lanmissouri Mandevilla sanderi
AU5585P (en) Lanutah Mandevilla sanderi
AU5594P (en) Lanoregon Mandevilla sanderi
AU5598P (en) Lanidaho Mandevilla sanderi
AU5584P (en) Laniowa Mandevilla sanderi
AU5597P (en) Lancalifornia Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5596P (en) Lannevada Mandevilla sanderi
AU5591P (en) Lanmontana Mandevilla sanderi
AU5287P (en) FLOMANPIW Mandevilla sanderi
AU5285P (en) FLOMANRER Mandevilla sanderi
AU5286P (en) FLOMANWHW Mandevilla sanderi
AU5288P (en) FLOMANTOG Mandevilla sanderi